newsfilter
← Latest News
GlobeNewswire·

Annovis Announces Launch of Proposed Public Offering

ANVS
  • Annovis Bio, Inc. (NYSE: ANVS) announced a proposed underwritten public offering of common stock, pre-funded warrants, and accompanying warrants.
  • Canaccord Genuity is acting as the sole bookrunner for the offering.
  • The company intends to use net proceeds for the continued clinical development of buntanetap for Alzheimer's disease (AD) and Parkinson's disease (PD), plus working capital and general corporate purposes.
  • The offering is being conducted pursuant to an effective shelf registration statement on Form S-3 (No. 333-276814) filed with the SEC.
  • The proposed offering is subject to market conditions, with no assurance regarding completion, size, or terms.
  • Annovis Bio is a Phase 3 clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, developing the oral therapy buntanetap to target neurodegenerative proteins.